|
|
|
| AR-A014418 inhibits the expression of SOX2 and promotes the sensitivity of chondrosarcoma to cisplatin |
| LIU Fanrong1, TENG Honglin1, XIAO Jianru1, 2. |
1.Department of Spine Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China; 2.Department of Orthopedic Oncology, Shanghai
Changzheng Hospital, Shanghai 200003, China |
|
| Cite this article: |
|
LIU Fanrong,TENG Honglin,XIAO Jianru. AR-A014418 inhibits the expression of SOX2 and promotes the sensitivity of chondrosarcoma to cisplatin[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(4): 291-297,304.
|
|
|
|
Abstract Objective: To investigate the effect of GSK3β gene on human chondrosarcoma cell lines HCS 2/8 and SW 1353 by cell experiments. Methods: CCK-8 and colony formation assay were used to detect cell proliferation ability; Transwell assay was used to detect cell invasion ability; wound-healing assay was used to detect cell migration ability; Western blot was used to detect changes of SOX2 in cells; combination experiments were made to verify the effect of AR-A014418 combined with cisplatin. Results: Knockdown of GSK3β significantly inhibited the proliferation and invasion ability of chondrosarcoma (P<0.05). With GSK3β knockdown, the protein expression of SOX2 in cells decreased (P<0.05), and its mRNA level did not change significantly (P>0.05). AR-A014418 could effectively inhibit the expression of SOX2 in CS cells, and the combination of AR and cisplatin produced significant effect. Conclusion: Knockdown of GSK3β can inhibit the protein expression of SOX2 and promote the sensitivity of chondrosarcoma to chemotherapy. As a specific inhibitor of GSK3β, AR-A014418 has the function of killing chondrosarcoma cells, which has good combination effect with cisplatin.
|
|
Received: 06 February 2023
|
| |
|
|
|
|
|
|
